Specify a stock or a cryptocurrency in the search bar to get a summary
Tarsus Pharmaceuticals Inc
TARSTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Address: 15440 Laguna Canyon Road, Irvine, CA, United States, 92618
Analytics
WallStreet Target Price
59 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TARS
Dividend Analytics TARS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TARS
Stock Valuation TARS
Financials TARS
Results | 2019 | Dynamics |